As patents for the first biological medicines expire, the number of new follow-on or biosimilar products is increasing. They are also receiving regulatory approval and being launched onto the market. At this meeting, experts in biological medicines will discuss the challenges facing developers of biosimilar drugs, from designing sound immunogenicity studies, to securing market access. The meeting will also discuss the therapeutic areas being targeted by these medicines, patent litigation and substitution.
